CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Oscient Pharmaceuticals Corporation is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Oscient Pharmaceuticals Corporation
1000 Winter Street
Suite 2200
Phone: (781) 398-2300p:781 398-2300 Waltham, MA  02451  United States Ticker: OSCIQOSCIQ
This company is no longer actively traded on any major stock exchange.
Business Summary
Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing United States Food and Drug Administration (FDA) approved products in the United States. The Company markets two products: ANTARA (fenofibrate) capsules, a cardiovascular product, and FACTIVE (gemifloxacin mesylate) tablets, a fluoroquinolone antibiotic. ANTARA is approved by the FDA to treat hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia in combination with a healthy diet. The Company also has late-stage antibiotic candidate, Ramoplanin for the treatment of Clostridium difficile-associated disease (CDAD). In July 2009, Oscient Pharmaceuticals Corporation and its wholly owned subsidiary, Guardian II Acquisition Corporation, announced that each filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Massachusetts.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/200812/31/2008YesYesYes--

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board David K.Stone 52 7/20/2005 8/21/2001
President, Chief Executive Officer, Director Stephen M.Rauscher 55 2/1/2004 1/1/1993
Chief Financial Officer, Executive Vice President Philippe M.Maitre 52 2/1/2008 5/22/2006
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Guardian II Acquisition Corporation 1000 Winter Street Waltham MA United States

Business Names
Business Name
Genome Therapeutics Corp.
OSCIQ

General Information
Number of Employees: 213 (As of 3/20/2009)
Outstanding Shares: 39,431,805 (As of 4/15/2009)
Shareholders: 471
Stock Exchange: NASD
Federal Tax Id: 42297484
Fax Number: (781) 893-9535


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023